Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Centrally acting muscle relaxant with anticholinergic effects.
At last update no published on excretion in breast milk data were found. Even on humans pharmacokinetic data is barely found.
Its anticholinergic effect has a theoretical risk of inhibiting lactation especially during the early postpartum weeks.
Until more data about this drug regarding breastfeeding is available, safer known alternatives should be of choice, especially in the neonatal period and in case of prematurity.
If administered during breastfeeding, use small doses and monitor drowsiness and adequate feeding of the infants.
(Not to be confused with the trademark Pridinol, which in some countries corresponds to Terfenadine)